Schlafen (SLFN) genes belong to a vertebrate gene family encoding proteins with high
sequence homology. However, each SLFN is functionally divergent and differentially …

Pharmacological inhibition of the ataxia telangiectasia and Rad3-related protein
serine/threonine kinase (ATR; also known as FRAP-related protein (FRP1)) has emerged as …

Exatecan and deruxtecan are antineoplastic camptothecin derivatives in development as
tumor-targeted-delivery warheads in various formulations including peptides, liposomes …

Antibody–drug conjugates (ADC) allow the delivery of cytotoxic chemotherapeutic agents to
tumors. Two ADC delivering topoisomerase I (TOP1) poisons (Enhertu and Trodelvy) have …

DNA methylation is a key regulator of gene expression and a clinical therapeutic predictor.
We examined global DNA methylation beyond the generally used promoter areas in human …

Antibody-drug conjugates (ADCs) are a promising targeted cancer therapy; however, patient
selection based solely on target antigen expression without consideration for cytotoxic …

Recent advances in understanding the tumor's biology in line with a constantly growing
number of innovative technologies have prompted characterization of patients' individual …

PARP inhibitors (PARPis) were initially developed as DNA repair inhibitors that inhibit the
catalytic activity of PARP1 and PARP2 and are expected to induce synthetic lethality in …

Few treatment options exist for pleural mesothelioma (PM), which is a progressive malignant
tumor. However, the efficacy of molecular-targeted monotherapy is limited, and further …

Proliferating cells rely on DNA replication to ensure accurate genome duplication. Cancer
cells, including breast cancer cells, exhibit elevated replication stress (RS) due to the …